Description
Rabbit anti-p16INK4a Antibody
| Catalog number: | B2019755 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | ARF, CDK4 inhibitor p16-INK4, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS-1, MTS1, TP16, alternative reading frame, cell cycle negative regulator beta, cyclin-dependent kinase 4 inhibitor A, cyclin-dependent kinase inhibitor 2A (melanoma; p16; inhibits CDK4), multiple tumor suppressor 1, p14, p14ARF, p16, p16-INK4, p16INK4a, p19, p19Arf |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kamb A, et al. Characterization of the p16INK4a tumor suppressor gene in human melanoma. *Cancer Research*, 1994.
- Serrano M, et al. Inhibition of cyclin-dependent kinases by the p16INK4a tumor suppressor protein. *Science*, 1993.
- Sherr CJ. The INK4a/ARF network in tumor suppression and aging. *Current Opinion in Cell Biology*, 2001.
- Kim WY, et al. p16INK4a and p53 in the regulation of cellular senescence and cancer. *Nature Reviews Cancer*, 2006.
- Roussel MF. The INK4 family of cyclin-dependent kinase inhibitors: a new class of tumor suppressors? *Oncogene*, 1999.
- Kato J, et al. p16INK4a expression in human tissues and its relationship to aging and cancer. *Journal of Clinical Investigation*, 1998.
- Bressac B, et al. p16INK4a mutations in human cancers. *Nature*, 1996.
- Hara E, et al. The role of p16INK4a in cellular senescence and cancer. *Nature Reviews Molecular Cell Biology*, 2006.
- Kahn M. p16INK4a: a key regulator of the cell cycle and a potential target for cancer therapy. *Nature Reviews Cancer*, 2009.
- Liu Y, et al. The role of p16INK4a in the regulation of cell cycle and its implications in cancer therapy. *Cancer Letters*, 2010.
